Upgrade: Phase 1 combination trial of the NaPi2b-directed dolaflexin antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer

被引：0

作者：

Lakhani, Nehal ^{[1
]}

Burns, Timothy ^{[2
]}

Barve, Minal ^{[3
]}

Edenfield, Jeffery ^{[4
]}

Hays, John ^{[5
]}

Zarwan, Corrine ^{[6
]}

Werner, Theresa ^{[7
]}

Anderson, Charles ^{[8
]}

Buscema, Joseph ^{[9
]}

Bernardo, Patricia ^{[10
]}

Keeton, Erika ^{[11
]}

Carrington, Cassandra ^{[10
]}

Burger, Robert ^{[10
]}

机构：

[1] START Midwest, Grand Rapids, MI USA

[2] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA

[3] Mary Crowley Res Ctr, Dallas, TX USA

[4] Prisma Hlth Canc Inst, Seneca, SC USA

[5] Ohio State Univ, James Canc Ctr, Columbus, OH 43210 USA

[6] Lahey Hosp & Med Ctr, Burlington, MA USA

[7] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[8] Willamette Valley Canc Inst, Eugene, OR USA

[9] Arizona Oncol Associates PC, Chandler, AZ USA

[10] Mersana Therapeut, Cambridge, MA USA

[11] GlaxoSmithKline, Brentford, England

来源：

GYNECOLOGIC ONCOLOGY | 2022年 / 166卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

588

引用

页码：S285 / S286

页数：2

共 50 条

[1] UPGRADE: PHASE 1 COMBINATION TRIAL OF THE NAPI2B-DIRECTED ANTIBODY DRUG CONJUGATE (ADC) UPIFITAMAB RILSODOTIN (UPRI; XMT-1536) IN PATIENTS WITH OVARIAN CANCER
Hays, John
Werner, Theresa
Lakhani, Nehal
Edenfield, Jeffrey
Buscema, Joseph
Burns, Timothy
Carrington, Cassandra
Keeton, Erika
Burger, Robert
Anderson, Charles
[J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A235 - A235
[2] Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer
Richardson, Debra
Hamilton, Erika
Barve, Minal
Anderson, Charles
Taylor, Sara
Lakhani, Nehal
Buscema, Joseph
Tolcher, Anthony
Zarwan, Corrine
Werner, Theresa
Hays, John
Arend, Rebecca
Edenfield, Jeffery
Putiri, Emily
Bernardo, Patricia
Burger, Robert
Matulonis, Ursula
[J]. GYNECOLOGIC ONCOLOGY, 2022, 166 : S48 - S48
[3] Optimizing the dose of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC): A post-hoc analysis of a phase 1b expansion study in ovarian cancer
Monk, Bradley
Concin, Nicole
Richardson, Debra
Ray-Coquard, Isabelle
Pothuri, Bhavana
Marth, Christian
Bernardo, Patricia
Burger, Robert
Im, Ellie
Aldairy, Wassim
Coleman, Robert
Mirza, Mansoor
[J]. GYNECOLOGIC ONCOLOGY, 2022, 166 : S166 - S166
[4] UPLIFT (ENGOT-OV67/GOG-3048) A PIVOTAL COHORT OF THE XMT-1536-1 TRIAL OF UPIFITAMAB RILSODOTIN (XMT-1536; UPRI), A NAPI2B-DIRECTED ANTIBODY DRUG CONJUGATE (ADC) IN PLATINUM-RESISTANT OVARIAN CANCER
Richardson, Debra
Perez Fidalgo, Jose Alejandro
Gonzalez-Martin, Antonio
Oaknin, Ana
Hamilton, Erika
Hays, John
Pothuri, Bhavana
Papadopoulos, Kyriakos
Taylor, Sara
Huang, Marilyn
Lee, Yeh-Chen
Krivak, Thomas
Moreno-Garcia, Victor
Calvo, Emiliano
Randall, Leslie
Starks, David
Ross, Malcom
Duska, Linda
Gao, Bo
Poka, Robert
Putiri, Emily
Barrett, Jamie
Demars, Leslie
Concin, Nicole
[J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A241 - A241
[5] UPGRADE-A: Phase 1 expansion trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi) in combination with carboplatin in patients with high-grade serous ovarian cancer (HGSOC)
Hays, John L.
Friedman, Claire Frances
Lakhani, Nehal
Anderson, Charles K.
Buscema, Joseph
Duska, Linda R.
Hamilton, Erika P.
Taylor, Sarah E.
Carrington, Cassandra
Burger, Robert Allen
Werner, Theresa Louise
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[6] Uplift (ENGOT-ov67): A pivotal cohort to evaluate XMT-1536 (upifitamab rilsodotin), a NaPi2b-directed antibody drug conjugate for platinum-resistant ovarian cancer.
Richardson, Debra L.
Hamilton, Erika P.
Oaknin, Ana
Randall, Leslie M.
Banerjee, Susana N.
Taylor, Sara Kristina
Mileshkin, Linda R.
Coleman, Robert L.
Monk, Bradley J.
Mirza, Mansoor Raza
Bernardo, Patricia
Mosher, Rebecca
Jansen, Valerie Malyvanh
Savarese, Antonella
Van Gorp, Toon
Madry, Radoslaw
Ray-Coquard, Isabelle Laure
Concin, Nicole
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[7] Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate
Hamilton, E. P.
Barve, M. A.
Tolcher, A. W.
Buscema, J.
Papadopoulos, K. P.
Zarwan, C.
Anderson, C. K.
Doroshow, D.
Wang, D.
Huebner, D.
Jansen, V. M.
Jarlenski, D.
Mosher, R.
Kaufman, J.
Moore, K. N.
Richardson, D. L.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S627 - S628
[8] UP-NEXT (GOG-3049/ENGOT-OV71-NSGO-CTU): A STUDY OF UPIFITAMAB RILSODOTIN (UPRI), A NAPI2B-DIRECTED ANTIBODY DRUG CONJUGATE (ADC) IN PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER
Richardson, Debra
Harter, Philipp
O'Malley, David
Gonzalez-Martin, Antonio
Herzog, Thomas
Rogalski, Caroline
Burger, Robert
Mirza, Mansoor
[J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A241 - A241
[9] COMPARISON OF NAPI2B EXPRESSION FROM PAIRED TISSUE SAMPLES IN A CLINICAL STUDY OF UPIFITAMAB RILSODOTIN (UPRI; XMT-1536) SUPPORTS A STRATEGY OF TESTING IN ARCHIVE MATERIAL
Richardson, Debra
Barve, Minal
Saltos, Andreas
Papadopoulos, Kyriakos
Hays, John
Tolcher, Anthony
Ellard, Susan
Doroshow, Deborah
Mitchell, Paul
Zarwan, Corrine
Werner, Theresa
Anderson, Charles
Spira, Alex
Mileshkin, Linda
Bradshaw, Chelsea
Demars, Leslie
Mosher, Rebecca
Hamilton, Erika
[J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A55 - A56
[10] Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b.
Tolcher, Anthony W.
Ulahannan, Susanna Varkey
Papadopoulos, Kyriakos P.
Edenfield, William Jeffery
Matulonis, Ursula A.
Burns, Timothy F.
Mosher, Rebecca
Fielman, Barbara
Hailman, Eric
Burris, Howard A.
Moore, Kathleen N.
Hamilton, Erika Paige
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →